Trending

complement therapeutics

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris,

X

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

https://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/

3rd Annual Complement-based Drug Development Summit 2019

3rd Annual Complement-based Drug Development Summit 2019

November 13-15, 2019 | Boston, MA

X

3rd Annual Complement-based Drug Development Summit 2019

https://pharmaphorum.com/events/3rd-annual-complement-based-drug-development-summit-2019/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com